Oncotarget · 2016 · 36 citations · 18 references
Life SciencesOncologyPathologyMolecular OncologyProteomicsTumor ImmunologyCancer BiomarkersMass Spectrometry-based ProteomicsProteomic BiomarkersTumor AntigensTumor MarkersTumor-associated AntigensAntibodiesClinicopathologic FeaturesEarly Detection Of RecurrenceEarly Recurrence PredictionMass Spectrometry ProteomicsPrognostic Marker AssessmentProteomics-based Antigen DiscoveryTumor Antigen Identification
// Yuan-Quan Yu 1, * , Liang Wang 1, * , Yun Jin 1 , Jia-Le Zhou 1 , Yan-Hua Geng 2 , Xing Jin 1 , Xiao-Xiao Zhang 1 , Jun-Jie Yang 1 , Cheng-Ming Qian 1 , Dong-Er Zhou 1 , Da-Ren Liu 1 , Shu-You Peng 1 , Yan Luo 3 , Lei Zheng 4 , Jiang-Tao Li 1 1 Department of Surgery, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China 2 Department of Pathology, The Red Cross Hospital in Hangzhou, Hangzhou, Zhejiang, China 3 Center for Cancer Research and Department of Biochemistry, Zhejiang University School of Basic Medical Sciences, Hangzhou, Zhejiang, China 4 The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA * These authors have contributed equally to this work Correspondence to: Jiang-Tao Li, e-mail: zjulijiangtao@163.com Lei Zheng, e–mail: lzheng6@jhmi.edu Yan Luo, e–mail: luoyan2011@zju.edu.cn Keywords: hepatocellular carcinoma, microvascular invasion, sero-proteomics, biomarker, diagnosis Received: September 08, 2015 Accepted: February 05, 2016 Published: February 23, 2016 ABSTRACT Microvascular invasion (MVI) of hepatocellular carcinoma (HCC) is a major risk factor for early recurrence and poor survival after curative surgical therapies. However, MVI can only be diagnosed by pathological examination following resection. The aim of this study is to identify serologic biomarkers for predicting MVI preoperatively to help facilitate treatment decisions. We used the sero-proteomic approach to identify antigens that induce corresponding antibody responses either specifically in the serum from MVI (+) patients or from MVI (−) patients. Six antigens were subsequently identified as HSP 70, HSP 90, alpha-enolase (Eno-1), Annexin A2, glutathione synthetase and beta-actin by mass spectrometry. The antibodies titers in sera corresponding to four of these six antigens were measured by ELISA and compared between 35 MVI (+) patients and 26 MVI (−) patients. The titers of anti-HSP 70 antibodies were significantly higher in MVI (−) patients than those in MVI (+) patients; and the titers of anti-Eno-1 antibodies were significantly lower in MVI (−) patients than those in MVI (+) patients. The results were subjected to multivariate analysis together with other clinicopathologic factors, suggesting that antibodies against HSP 70 and Eno-1 in sera are potential biomarkers for predicting MVI in HCC prior to surgical resection. These biomarkers should be further investigated as potential therapeutic targets.
18
Mass Spectrometric Sequencing of Proteins from Silver-Stained Polyacrylamide Gels
Andrej Shevchenko, Matthias Wilm, Ole Vorm et al. · Analytical Chemistry · 1996 · 9.1K citations
Management of Hepatocellular Carcinoma *
Jordi Bruix, Morris Sherman · Hepatology · 2005 · 5.9K citations · Full text
TNM seventh edition: What's new, what's changed
Leslie H. Sobin, Carolyn C. Compton · Cancer · 2010 · 473 citations · Full text